Medicenna Therapeutics Corp (MDNAF)
OTHER OTC:MDNAF
MDNAF Stock Chart & Stats
$0.62
-$0.06(-5.24%)
At close: 4:00 PM EST
$0.62
-$0.06(-5.24%)
Day’s Range― - ―
52-Week Range$0.25 - $1.43
Previous CloseN/A
Volume34.40K
Average Volume (3M)42.08K
Market Cap
$20.14M
Enterprise Value$18.12M
Total Cash (Recent Filing)$10.61M
Total Debt (Recent Filing)$205.00K
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Jun 25, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding68,737,340
10 Day Avg. Volume52,191
30 Day Avg. Volume42,077
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.93
Price to Sales (P/S)0.00
P/FCF Ratio-4.55
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-312.36
Enterprise Value/Ebitda-0.84
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.25
Revenue Forecast (FY)$656.96K
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy SignalAn improved response rate to 38% in a secondary immune checkpoint inhibitor–resistant cutaneous melanoma cohort suggests meaningful clinical activity that could enhance investor confidence.
Industry Partnering And Deal FlowRising pharma interest and recent high-value deals in anti-PD-1 bispecifics highlight growing commercial appetite, potentially attracting partners and licensing opportunities.
Platform And Pipeline PotentialOngoing promise of MDNA11 and advances in PD-1/IL-2 bispecific approaches point to differentiated therapeutic positioning and potential long-term pipeline value.
Bears Say
Insufficient Data ValidationLimited additional validation from recent data raises questions about reproducibility and increases the need for confirmatory studies before broader adoption.
Low Monotherapy EfficacyA monotherapy response rate of 8% signals limited single-agent effectiveness and may trigger investor skepticism about standalone therapeutic prospects.
Medicenna Therapeutics Corp News
MDNAF FAQ
What was Medicenna Therapeutics Corp’s price range in the past 12 months?
Medicenna Therapeutics Corp lowest stock price was $0.25 and its highest was $1.43 in the past 12 months.
What is Medicenna Therapeutics Corp’s market cap?
Medicenna Therapeutics Corp’s market cap is $20.14M.
When is Medicenna Therapeutics Corp’s upcoming earnings report date?
Medicenna Therapeutics Corp’s upcoming earnings report date is Jun 25, 2026 which is tomorrow.
How were Medicenna Therapeutics Corp’s earnings last quarter?
Medicenna Therapeutics Corp released its earnings results on Feb 13, 2026. The company reported -$0.035 earnings per share for the quarter, the consensus estimate of -$0.035 by $0.
Is Medicenna Therapeutics Corp overvalued?
According to Wall Street analysts Medicenna Therapeutics Corp’s price is currently Overvalued.
Does Medicenna Therapeutics Corp pay dividends?
Medicenna Therapeutics Corp does not currently pay dividends.
What is Medicenna Therapeutics Corp’s EPS estimate?
Medicenna Therapeutics Corp’s EPS estimate is -0.04.
How many shares outstanding does Medicenna Therapeutics Corp have?
Medicenna Therapeutics Corp has 68,737,340 shares outstanding.
What happened to Medicenna Therapeutics Corp’s price movement after its last earnings report?
Medicenna Therapeutics Corp reported an EPS of -$0.035 in its last earnings report, expectations of -$0.035. Following the earnings report the stock price went up 8.993%.
Which hedge fund is a major shareholder of Medicenna Therapeutics Corp?
Currently, no hedge funds are holding shares in MDNAF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Medicenna Therapeutics Corp
Medicenna Therapeutics Corp. is an immunotherapy firm focused on creating and commercializing Superkines and "empowered Superkines" to combat cancer and various other illnesses. Their primary candidate, MDNA55, an interleukin-4 (IL-4) empowered cytokine, has successfully finished Phase IIb trials for recurrent glioblastoma and is also being investigated for other brain and non-brain tumor types in earlier developmental stages. The company's pipeline also includes MDNA11, an improved IL-2 variant designed to stimulate immune responses against cancer; MDNA209, an IL-2 antagonist aimed at autoimmune conditions like multiple sclerosis and graft-versus-host disease; MDNA413, a dual IL-4/IL-13 antagonist for use in cancer immunotherapy; and MDNA132, an IL-13 Superkine targeting solid tumors. Furthermore, Medicenna utilizes its BiSKITs platform to engineer bespoke Superkines by joining them with proteins, antibodies, cytokines, or other Superkines. The company's main office is located in Toronto, Canada.
Technical Analysis
Satellos Bioscience
―
Arch Biopartners
―
Covalon Technologies
―
ME Therapeutics Holdings, Inc.
―
Onco-Innovations Ltd.
―
Ownership Overview
18.15% Insiders
0.17% Other Institutional Investors
81.68% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---